All In Biotech

Drug Trial Radar · NCT07078695

A Trial of SHR-1139 in Healthy Volunteers

A Phase 1, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Subcutaneous/Intravenous Administered SHR-1139 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 19, 2025

Primary completion

Nov 9, 2026

Study completion Jan 30, 2027

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose of SHR-1139 in healthy volunteers

Conditions

  • Psoriasis

Interventions

  • SHR-1139 InjectionDrug

    Single dose of SHR-1139 given subcutaneously (dose level 1 )

  • SHR-1139 InjectionDrug

    Single dose of SHR-1139 given subcutaneously (dose level 2 )

  • SHR-1139 InjectionDrug

    Single dose of SHR-1139 given intravenously (dose level 3)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK profile of SHR-1139 after a single administrationTime frame: Start of Treatment to end of study (Day 253)
  2. PK profile of SHR-1139 after a single administrationTime frame: From time 0 to infinity after SHR-1139 administration (Day 253)
  3. PK profile of SHR-1139 after a single administration:Time frame: Start of Treatment to end of study (Day 253)
  4. PK profile of SHR-1139 after a single administrationTime frame: Start of Treatment to end of study (Day 253)
  5. Immunogenicity profile of SHR-1139 after a single dose administrationTime frame: Day 253

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Linear

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.